Onset of Crohn's disease induced by etanercept therapy: A case report;Le cas clinique du mois - Maladie de Crohn induite par l'étanercept: À propos d'une nouvelle observation

Revue Medicale de Liege

Volumn 67, Issue 12, 2012, Pages 619-622

  Mrabet, D ^a   Selmi, A ^a   Filali, A ^a   Sahli, H ^a   Sellami, S ^a  

^a LA RABTA HOSPITAL   (Tunisia)

Author keywords

Ankylosing spondylitis; Crohn's disease; Etanercept; Side effect; Tumor necrosis factor inhibitor

Indexed keywords

ETANERCEPT; INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CASE REPORT; COLONOSCOPY; CROHN DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE;

ADULT; ANTIBODIES, MONOCLONAL; COLONOSCOPY; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING;

EID: 84872328402     PISSN: 0370629X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Song IH, Appel H, Haibel H, et al.- New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol, 2008, 35, 532-536. (Pubitemid 351374434)
2. Brandt J, Listing J, Haibel H, et al.- Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology, 2005, 444, 342-348. (Pubitemid 40361291)
3. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P.- Efficacy of etanercept for the treatment of Crohn's-related spondyloarthritis but not colitis. Ann Rheum Dis, 2003, 62, 74-76. (Pubitemid 36005801)
4. Davis JC, Van Der Heijde D, Braun J, et al.- Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis : a randomized controlled trial. Arthritis Rheum, 2003, 48, 3230-3236. (Pubitemid 37409337)
5. Haraoui B, Krelenbaum M.- Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor ggent etanercept for ankylosing spondylitis : possible mechanisms of action. Semin Arthritis Rheum, 2009, 39, 176-181.
6. Oh J, Arkfeld DG, Horwitz DA.- Development of Crohn's disease in a patient taking etanercept. J Rheumatol, 2005, 32, 752-753. (Pubitemid 40524713)
7. De Keyser F, Elewaut D, De Vos M, et al.- Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am, 1998, 24, 785-813.
8. Mielants H, Veys EM.- The bowel and spondylarthritis: a clinical approach In : Calin A, Taurog JD, editors. The spondyloarthropathies. New York, Oxford University Press, 1998, 129-157.
9. Leirisalo-Repo M.- Prognosis, course of disease and treatment of the spondyloarthropathies. Rheum Dis Clin North Am, 1998, 24, 737-751. (Pubitemid 28524021)
10. Rudwaleit M, Baeten D.- Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol, 2006, 20, 451-471.
11. Mielants H, Veys EM, Cuvelier C, et al.- The evolution of spondylarthropathies in relation to gut histology. J Rheumatol, 1995, 22, 2279-2284.
12. Braun J, Baraliakos X, Listing J, et al.- Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum, 2007, 57, 639-647. (Pubitemid 46764055)
13. Targan SR, Hanauer SB, van Deventer SJ, et al.- A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor for Crohn's disease. N Engl J Med, 1997, 337, 1029-1035.
14. Rutgeerts P, D'Haens G, Targan S, et al.- Efficacy and safety of retreatment with antitumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology, 1999, 117, 761-769. (Pubitemid 29468216)
15. Sieper J, Van Den Brande J.- Diverse effects of infliximab and etanercept on T lymphocytes. Semin Arthritis Rheum, 2005, 34, 23-27.
16. Zou J, Rudwaleit M, Brandt J, et al.- Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum, 2003, 48, 780-790. (Pubitemid 36302016)
17. Berg L, Lampa J, Rogberg S, et al.- Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNF-α receptors. Ann Rheum Dis, 2001, 60, 133-139. (Pubitemid 32102204)
18. Zou J, Rudwaleit M, Brandt J, et al.- Up-regulation of the production of tumor necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis, 2003, 62, 561-564. (Pubitemid 36606291)
19. Sfikakis PP, Illiopoulos A, Elezoglou A, et al.- Psoriasis induced by anti-tumor necrosis factor therapy : a paradoxical adverse reaction. Arthritis Rheum, 2005, 52, 2513-2518. (Pubitemid 41117439)
20. Ramos-Casals M, Brito-Zeron P, Munoz S, et al.- Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine, 2007, 86, 242-251. (Pubitemid 47067483)
21. Delaporte E.- Affections infl ammatoires à médiation immunitaire et psoriasis. Ann Dermatol, 2008, 135, S269-S274.
22. Gregersen PK.- Modern genetics, ancient defenses, and potential therapies. N Engl J Med, 2007, 356, 1263-1265.
23. Xavier RJ, Podolsky DK.- Unravelling the pathogenesis of inflammatory bowel disease. Nature, 2007, 448, 427-434. (Pubitemid 47123518)
24. Ho P, Bruce IN, Silman A, et al.- Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum, 2005, 52, 3596-3602. (Pubitemid 41612229)